Capstone Investment Advisors
CARM

Capstone Investment Advisors’s Carisma Therapeutics CARM Stock Holding History

Capstone Investment Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,249
Closed -$117K – 1725
2021
Q1 		$117K Sell
2,249
-2,433
-52% -$115K ﹤0.01% 1503
2020
Q4 		$126K Buy
+4,682
New +$119K ﹤0.01% 1523

Other funds holding CARM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capstone Investment Advisors's CARM Position: Q2 2021 in Review

Capstone Investment Advisors sold out of Carisma Therapeutics (CARM) in Q2 2021, closing a stake of 2,249 shares — an estimated $117K sold.

Capstone Investment Advisors first reported a position in CARM in Q4 2020 and held it in 2 quarters. The position peaked at $126K in Q4 2020. 105 funds tracked by Wall St. Rank hold CARM as of Q2 2021.

  • Capstone Investment Advisors reported no remaining Carisma Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 2,249 Carisma Therapeutics shares in Q2 2021, an estimated $117K.
  • Capstone Investment Advisors first reported a position in Carisma Therapeutics in Q4 2020 and held it in 2 quarters.
  • Capstone Investment Advisors's Carisma Therapeutics position peaked at $126K in Q4 2020.
  • 105 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2021.

Based on Capstone Investment Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.